Zn(II) porphyrin-encapsulated MIL-101 for photodynamic therapy of breast cancer cells

Lasers Med Sci. 2023 Jun 28;38(1):151. doi: 10.1007/s10103-023-03813-2.

Abstract

The photodynamic treatment is a non-aggressive and clinically accepted procedure for removing selected cancer cells with the activation of a photosensitizer agent at a specific light. In this study, the zinc porphyrin (Zn[TPP]) was prepared and encapsulated into the MIL-101 (Zn[TPP]@MIL-101). It was used in photodynamic therapy (PDT) against MCF-7 breast cancer cells under a red light-emitting diode. The structure, morphology, surface area, and compositional changes were investigated using conventional characterization methods including FTIR, FESEM, EDX, and BET analyses. The MTT assay was performed under light and dark conditions to explore the ability of Zn[TPP]@MIL-101 in PDT. The results have demonstrated the IC50 of 14.3 and 81.6 mg/mL for light and dark groups, respectively. As the IC50 revealed, the Zn[TPP]@MIL-101 could efficiently eradicate cancer cells using PDT.

Keywords: Breast cancer; Metal–organic framework; Photodynamic therapy; Porphyrin.

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Cell Line, Tumor
  • Female
  • Humans
  • Photochemotherapy* / methods
  • Photosensitizing Agents / therapeutic use
  • Porphyrins* / therapeutic use
  • Zinc / pharmacology
  • Zinc / therapeutic use

Substances

  • Porphyrins
  • MIL-101
  • Photosensitizing Agents
  • Zinc